摘要
目的探讨培美曲塞联合顺铂治疗表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)耐药非小细胞肺癌(NSCLC)的疗效。方法将120例EGFR-TKI耐药NSCLC患者随机分为观察组与对照组,两组样本量均为60例,其中观察组采用培美曲塞联合顺铂治疗,对照组采用多西紫杉醇联合顺铂治疗。结果两组患者总缓解率(RR)、疾病控制率(DCR)、总生存期(OS)相比差异无统计学意义(P>0.05),观察组无疾病进展时间(PFS)显著长于对照组,差异有显著性(P<0.05)。观察组中吸烟患者与不吸烟患者的RR、DCR相比差异无统计学意义(P>0.05),但吸烟患者OS、PFS显著短于不吸烟患者,差异有显著性(P<0.05)。对照组中吸烟患者与不吸烟患者的RR、DCR相比差异无统计学意义(P>0.05),但吸烟患者OS、PFS显著短于不吸烟患者,差异有显著性(P<0.05)。结论培美曲塞联合顺铂与多西紫杉醇联合顺铂治疗EGFR-TKI耐药NSCLC的疗效大致相近,且吸烟对上述两个方案的疗效均有一定的影响。
Objective To investigate the efficacy of pemetrexed plus cisplatin in the treatment of non-small cell lung cancer（ NSCLC） patients with epidermal growth factor receptor tyrosine kinase inhibitor（ EGFR-TKI） resistance.Methods 120 cases of NSCLC with EGFR-TKI resistance were randomly divided into the observation group and the control group,and each group included 60 patients,the observation group was given pemetrexed plus cisplatin,while the control group received docetaxel plus cisplatin.Results The total remission rates（ RR）,disease control rates（ DCR）,overall survival（ OS） had no obvious differences between the 2 groups（ P 0.05）,while the progression-free survival（ PFS） in the observation group was obviously longer than that of the control group（ P 0.05）.In the observation group,RR,DCR had no obvious differences between smoking and non-smoking patients（ P 0.05）,while the OS,PFS in smoking patients was obviously shorter than those of non-smoking patients（ P 0.05）.In the control group,the RR,DCR had no obvious differences between smoking and non-smoking patients（ P 0.05）,while the OS,PFS in smoking patients was obviously shorter than those of non-smoking patients（ P 0.05）.Conclusion Pemetrexed plus cisplatin and docetaxel plus cisplatin have similar efficacy in the treatment of NSCLC patients with EGFR-TKI resistance,and smoking can influence the efficacy of these above 2 regimens.
出处
《实用癌症杂志》
2016年第11期1881-1883,共3页
The Practical Journal of Cancer
关键词
培美曲塞
多西紫杉醇
顺铂
非小细胞肺癌
Pemetrexed
Docetaxel
Cisplatin
Non-small cell lung cancer（NSCLC）
